Annual CFO
-$92.08 M
-$13.35 M-16.95%
31 December 2023
Summary:
Cara Therapeutics annual cash flow from operations is currently -$92.08 million, with the most recent change of -$13.35 million (-16.95%) on 31 December 2023. During the last 3 years, it has fallen by -$86.59 million (-1578.11%). CARA annual CFO is now -3354.79% below its all-time high of $2.83 million, reached on 31 December 2013.CARA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$13.98 M
-$1.55 M-12.44%
30 September 2024
Summary:
Cara Therapeutics quarterly cash flow from operations is currently -$13.98 million, with the most recent change of -$1.55 million (-12.44%) on 30 September 2024. Over the past year, it has increased by +$5.66 million (+28.82%). CARA quarterly CFO is now -117.04% below its all-time high of $82.09 million, reached on 31 December 2020.CARA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$74.24 M
+$5.66 M+7.08%
30 September 2024
Summary:
Cara Therapeutics TTM cash flow from operations is currently -$74.24 million, with the most recent change of +$5.66 million (+7.08%) on 30 September 2024. Over the past year, it has increased by +$23.97 million (+24.41%). CARA TTM CFO is now -419.38% below its all-time high of $23.25 million, reached on 30 September 2021.CARA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CARA Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -16.9% | +28.8% | +24.4% |
| 3 y3 years | -1578.1% | +0.9% | -419.4% |
| 5 y5 years | -312.9% | +45.5% | +27.5% |
CARA Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -1578.1% | at low | -1023.2% | +59.6% | -419.4% | +28.4% |
| 5 y | 5 years | -1578.1% | +15.7% | -117.0% | +63.5% | -419.4% | +39.5% |
| alltime | all time | -3354.8% | +15.7% | -117.0% | +63.5% | -419.4% | +39.5% |
Cara Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$13.98 M(+12.4%) | -$74.24 M(-7.1%) |
| June 2024 | - | -$12.44 M(-59.2%) | -$79.91 M(-9.1%) |
| Mar 2024 | - | -$30.45 M(+75.3%) | -$87.91 M(-4.5%) |
| Dec 2023 | -$92.08 M(+17.0%) | -$17.37 M(-11.6%) | -$92.08 M(-6.3%) |
| Sept 2023 | - | -$19.64 M(-3.9%) | -$98.22 M(-5.3%) |
| June 2023 | - | -$20.45 M(-40.9%) | -$103.77 M(+18.2%) |
| Mar 2023 | - | -$34.62 M(+47.2%) | -$87.82 M(+11.5%) |
| Dec 2022 | -$78.73 M(+31.0%) | -$23.51 M(-6.7%) | -$78.73 M(+39.4%) |
| Sept 2022 | - | -$25.19 M(+459.4%) | -$56.47 M(+24.4%) |
| June 2022 | - | -$4.50 M(-82.4%) | -$45.39 M(-26.7%) |
| Mar 2022 | - | -$25.52 M(+1950.2%) | -$61.89 M(+3.0%) |
| Dec 2021 | -$60.09 M(+995.1%) | -$1.25 M(-91.2%) | -$60.09 M(-358.5%) |
| Sept 2021 | - | -$14.12 M(-32.8%) | $23.25 M(+47.7%) |
| June 2021 | - | -$21.00 M(-11.4%) | $15.74 M(+73.1%) |
| Mar 2021 | - | -$23.72 M(-128.9%) | $9.10 M(-265.8%) |
| Dec 2020 | -$5.49 M(-95.0%) | $82.09 M(-479.7%) | -$5.49 M(-95.4%) |
| Sept 2020 | - | -$21.62 M(-21.8%) | -$118.74 M(-3.3%) |
| June 2020 | - | -$27.65 M(-27.8%) | -$122.76 M(+2.3%) |
| Mar 2020 | - | -$38.30 M(+22.9%) | -$120.00 M(+9.9%) |
| Dec 2019 | -$109.22 M(+389.8%) | -$31.17 M(+21.6%) | -$109.22 M(+6.6%) |
| Sept 2019 | - | -$25.64 M(+3.0%) | -$102.42 M(+5.3%) |
| June 2019 | - | -$24.90 M(-9.6%) | -$97.28 M(+210.2%) |
| Mar 2019 | - | -$27.53 M(+13.0%) | -$31.36 M(+40.6%) |
| Dec 2018 | -$22.30 M | -$24.36 M(+18.9%) | -$22.30 M(+138.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2018 | - | -$20.49 M(-150.0%) | -$9.35 M(-826.2%) |
| June 2018 | - | $41.02 M(-322.1%) | $1.29 M(-102.5%) |
| Mar 2018 | - | -$18.47 M(+61.8%) | -$51.66 M(-5.8%) |
| Dec 2017 | -$54.83 M(+15.7%) | -$11.41 M(+15.9%) | -$54.83 M(-3.1%) |
| Sept 2017 | - | -$9.85 M(-17.4%) | -$56.60 M(-5.1%) |
| June 2017 | - | -$11.93 M(-44.9%) | -$59.65 M(+0.8%) |
| Mar 2017 | - | -$21.64 M(+64.1%) | -$59.18 M(+24.9%) |
| Dec 2016 | -$47.38 M(+120.6%) | -$13.19 M(+2.2%) | -$47.38 M(+23.5%) |
| Sept 2016 | - | -$12.90 M(+12.6%) | -$38.36 M(+15.3%) |
| June 2016 | - | -$11.46 M(+16.5%) | -$33.27 M(+27.6%) |
| Mar 2016 | - | -$9.83 M(+135.9%) | -$26.07 M(+21.4%) |
| Dec 2015 | -$21.48 M(+21.7%) | -$4.17 M(-46.7%) | -$21.48 M(-7.2%) |
| Sept 2015 | - | -$7.82 M(+83.7%) | -$23.13 M(+16.8%) |
| June 2015 | - | -$4.25 M(-18.8%) | -$19.81 M(+0.1%) |
| Mar 2015 | - | -$5.24 M(-10.0%) | -$19.79 M(+12.2%) |
| Dec 2014 | -$17.64 M(-723.6%) | -$5.82 M(+29.8%) | -$17.64 M(+4.5%) |
| Sept 2014 | - | -$4.49 M(+5.9%) | -$16.88 M(+6.6%) |
| June 2014 | - | -$4.24 M(+37.1%) | -$15.84 M(-1117.0%) |
| Mar 2014 | - | -$3.09 M(-39.0%) | $1.56 M(-45.0%) |
| Dec 2013 | $2.83 M(-146.9%) | -$5.06 M(+47.2%) | $2.83 M(-64.2%) |
| Sept 2013 | - | -$3.44 M(-126.2%) | $7.89 M(-30.4%) |
| June 2013 | - | $13.15 M(-823.1%) | $11.33 M(-723.1%) |
| Mar 2013 | - | -$1.82 M | -$1.82 M |
| Dec 2012 | -$6.03 M(-11.9%) | - | - |
| Dec 2011 | -$6.84 M | - | - |
FAQ
- What is Cara Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Cara Therapeutics?
- What is Cara Therapeutics annual CFO year-on-year change?
- What is Cara Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Cara Therapeutics?
- What is Cara Therapeutics quarterly CFO year-on-year change?
- What is Cara Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Cara Therapeutics?
- What is Cara Therapeutics TTM CFO year-on-year change?
What is Cara Therapeutics annual cash flow from operations?
The current annual CFO of CARA is -$92.08 M
What is the all time high annual CFO for Cara Therapeutics?
Cara Therapeutics all-time high annual cash flow from operations is $2.83 M
What is Cara Therapeutics annual CFO year-on-year change?
Over the past year, CARA annual cash flow from operations has changed by -$13.35 M (-16.95%)
What is Cara Therapeutics quarterly cash flow from operations?
The current quarterly CFO of CARA is -$13.98 M
What is the all time high quarterly CFO for Cara Therapeutics?
Cara Therapeutics all-time high quarterly cash flow from operations is $82.09 M
What is Cara Therapeutics quarterly CFO year-on-year change?
Over the past year, CARA quarterly cash flow from operations has changed by +$5.66 M (+28.82%)
What is Cara Therapeutics TTM cash flow from operations?
The current TTM CFO of CARA is -$74.24 M
What is the all time high TTM CFO for Cara Therapeutics?
Cara Therapeutics all-time high TTM cash flow from operations is $23.25 M
What is Cara Therapeutics TTM CFO year-on-year change?
Over the past year, CARA TTM cash flow from operations has changed by +$23.97 M (+24.41%)